Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc. News
Eliem Therapeutics, Inc. Quantitative Score
About Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
Eliem Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Eliem Therapeutics, Inc. Financials
Table Compare
Compare ELYM metrics with: | |||
|---|---|---|---|
Earnings & Growth | ELYM | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ELYM | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ELYM | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ELYM | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Eliem Therapeutics, Inc. Income
Eliem Therapeutics, Inc. Balance Sheet
Eliem Therapeutics, Inc. Cash Flow
Eliem Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Eliem Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Chief Executive Officer, President & Director |
| Ms. Emily Pimblett | Chief Accounting Officer |
| Ms. Jo Palmer-Phillips Ph.D. | Chief Development Officer |
| Dr. Brett Kaplan M.B.A., M.D. | Chief Operating Officer & Principal Financial Officer |
| Dr. Nishi Rampal M.D. | Senior Vice President of Clinical Development |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Chief Executive Officer, President & Director | 1976 | -- | |
| Ms. Emily Pimblett | Chief Accounting Officer | Female | 1984 | -- |
| Ms. Jo Palmer-Phillips Ph.D. | Chief Development Officer | Female | -- | |
| Dr. Brett Kaplan M.B.A., M.D. | Chief Operating Officer & Principal Financial Officer | 1974 | -- | |
| Dr. Nishi Rampal M.D. | Senior Vice President of Clinical Development | -- |
Eliem Therapeutics, Inc. Insider Trades
| Date | 18 Sep |
| Name | Pimblett Emily |
| Role | CHIEF ACCOUNTING OFFICER |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 5000 |
| Date | 20 Sep |
| Name | Pimblett Emily |
| Role | CHIEF ACCOUNTING OFFICER |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1182 |
| Date | 20 Sep |
| Name | Pimblett Emily |
| Role | CHIEF ACCOUNTING OFFICER |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 9 |
| Date | 18 Sep |
| Name | Pimblett Emily |
| Role | CHIEF ACCOUNTING OFFICER |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 5000 |
| Date | 26 Aug |
| Name | Kaplan Brett |
| Role | Chief Operating Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 465000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 18 Sep | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Acquired | M-Exempt | 5000 |
| 20 Sep | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Disposed | S-Sale | 1182 |
| 20 Sep | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Disposed | S-Sale | 9 |
| 18 Sep | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Disposed | M-Exempt | 5000 |
| 26 Aug | Kaplan Brett | Chief Operating Officer | Acquired | A-Award | 465000 |